Donald Trump Eu hospital covid-19 president patient Coronavirus Cast Donald Trump Eu

Gilead contests WHO study that cast doubts on remdesivir's covid-19 benefits

Reading now: 578
www.livemint.com

"Solidarity" trial resultsThe WHO said on Thursday its "Solidarity" trial had concluded that remdesivir appeared to have little or no effect on 28-day mortality or length of hospital stays among patients with the respiratory disease.Used to treat TrumpThe antiviral medication was one of the drugs used to treat U.S.

President Donald Trump's coronavirus infection, and has been shown in previous studies to have cut time to recovery. The European Union is investigating it for possible kidney injury.The WHO trial was conducted in 11,266 adult patients in more than 30 countries.

The evidence was conclusive, the WHO said.Gilead said other trials of remdesivir, including with 1,062 patients that compared it with a placebo, showed the treatment cut.

Read more on livemint.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA